Journal
CANCERS
Volume 13, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/cancers13194783
Keywords
neuroblastoma; mouse model; MYCN; transcriptome analysis
Categories
Funding
- Kom op tegen Kanker research grant
- Research Foundation-Flanders (FWO) [1253321N, 1238420N, 12Q8319N, 1197617N]
- National Cancer Institute [K08CA245251]
- Damon Runyon Cancer Research foundation [DRSG 28-14]
- Alex's Lemonade Stand Foundation
- Rally Foundation for Childhood Cancer Research
- Stichting Villa Joep
- vzw Kinderkankerfonds
- CureSearch for Childrens Cancer Foundation
Ask authors/readers for more resources
Research on neuroblastoma has identified key factors related to tumor initiation and progression, as well as potential novel drug targets. The study found that roughly half of high-risk neuroblastoma patients exhibit MYCN gene amplification, and certain genes were significantly upregulated during tumor formation, suggesting their potential as targets for therapeutic intervention.
Simple Summary Neuroblastoma is a pediatric tumor originating from the sympathetic nervous system responsible for 10-15% of all childhood cancer deaths. Half of all neuroblastoma patients present with high-risk disease, of which nearly 50% relapse and die of their disease. In addition, standard therapies cause serious lifelong side effects and increased risk for secondary tumors. Further research is crucial to better understand the molecular basis of neuroblastomas and to identify novel druggable targets. Neuroblastoma tumorigenesis has to this end been modeled in both mice and zebrafish. Here, we present a detailed dissection of the gene expression patterns that underlie tumor formation in the murine TH-MYCN-driven neuroblastoma model. We identified key factors that are putatively important for neuroblastoma tumor initiation versus tumor progression, pinpointed crucial regulators of the observed expression patterns during neuroblastoma development and scrutinized which factors could be innovative and vulnerable nodes for therapeutic intervention. Roughly half of all high-risk neuroblastoma patients present with MYCN amplification. The molecular consequences of MYCN overexpression in this aggressive pediatric tumor have been studied for decades, but thus far, our understanding of the early initiating steps of MYCN-driven tumor formation is still enigmatic. We performed a detailed transcriptome landscaping during murine TH-MYCN-driven neuroblastoma tumor formation at different time points. The neuroblastoma dependency factor MEIS2, together with ASCL1, was identified as a candidate tumor-initiating factor and shown to be a novel core regulatory circuit member in adrenergic neuroblastomas. Of further interest, we found a KEOPS complex member (gm6890), implicated in homologous double-strand break repair and telomere maintenance, to be strongly upregulated during tumor formation, as well as the checkpoint adaptor Claspin (CLSPN) and three chromosome 17q loci CBX2, GJC1 and LIMD2. Finally, cross-species master regulator analysis identified FOXM1, together with additional hubs controlling transcriptome profiles of MYCN-driven neuroblastoma. In conclusion, time-resolved transcriptome analysis of early hyperplastic lesions and full-blown MYCN-driven neuroblastomas yielded novel components implicated in both tumor initiation and maintenance, providing putative novel drug targets for MYCN-driven neuroblastoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available